Idiopathic Interstitial Pneumonias: A Review of the Past and Emerging Therapies

1. Oliveira, DS, Araújo Filho, JA, Paiva, AFL, Ikari, ES, Chate, RC, Nomura, CH. Idiopathic interstitial pneumonias: Review of the latest American Thoracic Society/European Respiratory Society classification. Radiol Bras. 2018;51(5):321-327.
Google Scholar | Crossref | Medline2. Outcome of Patients with Idiopathic Pulmonary Fibrosis Admitted to the Intensive Care Unit|American Journal of Respiratory and Critical Care Medicine [Internet]. [cited August 5, 2021]. https://www.atsjournals.org/doi/full/10.1164/rccm.2104038.
Google Scholar3. Travis, WD, Costabel, U, Hansell, DM, et al. An Official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188(6):733-748.
Google Scholar | Crossref | Medline4. Troy, LK, Grainge, C, Corte, TJ, et al. Diagnostic accuracy of transbronchial lung cryobiopsy for interstitial lung disease diagnosis (COLDICE): A prospective, comparative study. Lancet Respir Med. 2020;8(2):171-181.
Google Scholar | Crossref | Medline5. Babiak, A, Hetzel, J, Krishna, G, et al. Transbronchial cryobiopsy: A new tool for lung biopsies. Respiration. 2009;78(2):203-208.
Google Scholar | Crossref | Medline6. Cottin, V, Cordier, J-F. Cryptogenic organizing pneumonia. Semin Respir Crit Care Med. 2012;33(5):462-475.
Google Scholar | Crossref | Medline7. Xu, W, Xiao, Y, Liu, H, Qin, M, Zheng, W, Shi, J. Nonspecific interstitial pneumonia: Clinical associations and outcomes. BMC Pulm Med. 2014;14:175.
Google Scholar | Crossref | Medline8. Hutchinson, JP, McKeever, TM, Fogarty, AW, Navaratnam, V, Hubbard, RB. Increasing global mortality from idiopathic pulmonary fibrosis in the twenty-first century. Ann Am Thorac Soc. 2014;11(8):1176-1185.
Google Scholar | Crossref | Medline9. Dove, EP, Olson, AL, Glassberg, MK. Trends in idiopathic pulmonary fibrosis–related mortality in the United States: 2000–2017. Am J Respir Crit Care Med. 2019;200(7):929-931.
Google Scholar | Crossref | Medline10. Raghu, G, Rochwerg, B, Zhang, Y, et al. An official ATS/ERS/JRS/ALAT clinical practice guideline: Treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am J Respir Crit Care Med. 2015;192(2):e3-19.
Google Scholar | Crossref | Medline11. Pirfenidone: Drug information - UpToDate [Internet]. [cited August 5, 2021]. https://www.uptodate.com/contents/pirfenidone-drug-information?search=pirfenidone&source=panel_search_result&selectedTitle=1∼24&usage_type=panel&kp_tab=drug_general&display_rank=1.
Google Scholar12. Nintedanib: Drug information - UpToDate [Internet]. [cited August 5, 2021]. https://www.uptodate.com/contents/nintedanib-drug-information?search=nintedanib&source=panel_search_result&selectedTitle=1∼24&usage_type=panel&kp_tab=drug_general&display_rank=1.
Google Scholar13. Laporta Hernandez, R, Aguilar Perez, M, Lázaro Carrasco, MT, Ussetti Gil, P. Lung transplantation in idiopathic pulmonary fibrosis. Med Sci. 2018;6(3):68.
Google Scholar14. Kondoh, Y, Taniguchi, H, Yokoi, T, et al. Cyclophosphamide and low-dose prednisolone in idiopathic pulmonary fibrosis and fibrosing nonspecific interstitial pneumonia. Eur Respir J. 2005;25(3):528-533.
Google Scholar | Crossref | Medline15. Bronchiolitis Obliterans Organizing Pneumonia | NEJM [Internet]. [cited August 5, 2021]. https://www.nejm.org/doi/10.1056/NEJM198501173120304?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed.
Google Scholar16. Wells, AU . Cryptogenic organizing pneumonia. Semin Respir Crit Care Med. 2001;22(4):449-460.
Google Scholar | Crossref | Medline17. Lazor, R, Vandevenne, A, Pelletier, A, Leclerc, P, Court-Fortune, I, Cordier, JF. Cryptogenic organizing pneumonia. Characteristics of relapses in a series of 48 patients. The Groupe d’Etudes et de Recherche sur les Maladles “Orphelines” Pulmonaires (GERM“O”P). Am J Respir Crit Care Med. 2000;162(2 Pt 1):571-577.
Google Scholar | Crossref | Medline18. Azathioprine: Drug information - UpToDate [Internet]. [cited August 5, 2021]. https://www.uptodate.com/contents/azathioprine-drug-information?search=azathioprine&source=panel_search_result&selectedTitle=1∼149&usage_type=panel&kp_tab=drug_general&display_rank=1.
Google Scholar19. Mycophenolate mofetil (Cellcept) and mycophenolate sodium (Myfortic): Drug information - UpToDate [Internet]. [cited August 5, 2021]. https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information?search=mycophenolate&source=panel_search_result&selectedTitle=1∼149&usage_type=panel&kp_tab=drug_general&display_rank=1.
Google Scholar20. Cyclophosphamide: Drug information - UpToDate [Internet]. [cited August 10, 2021]. https://www.uptodate.com/contents/cyclophosphamide-drug-information?search=cyclophosphamide%20&source=panel_search_result&selectedTitle=1∼149&usage_type=panel&kp_tab=drug_general&display_rank=1.
Google Scholar21. Noble, PW, Albera, C, Bradford, WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): Two randomised trials. Lancet. 2011;377(9779):1760-1769.
Google Scholar | Crossref | Medline | ISI22. King, TE, Bradford, WZ, Castro-Bernardini, S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083-2092.
Google Scholar | Crossref | Medline | ISI23. Dull, SK, Jagan, N, Moore, DR, DePew, ZS, Morrow, LE, Malesker, MA. Diffuse alveolar hemorrhage following pirfenidone initiation. J Pharm Pract. 2020;33(4):548-552.
Google Scholar | SAGE Journals | ISI24. Fabre, A, Nicholson, AG. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2020;382(8):780.
Google Scholar | Medline25. Kim, R, Meyer, KC. Therapies for interstitial lung disease: Past, present and future. Ther Adv Respir Dis. 2008;2(5):319-338.
Google Scholar | SAGE Journals26. Vancheri, C, Kreuter, M, Richeldi, L, Ryerson, CJ, Valeyre, D, Grutters, JC, et al. Nintedanib with add-on pirfenidone in idiopathic pulmonary fibrosis. Results of the INJOURNEY trial. Am J Respir Crit Care Med. 2018;197(3):356-363.
Google Scholar | Crossref | Medline27. Poletti, V, Romagnoli, M, Piciucchi, S, Chilosi, M. Current status of idiopathic nonspecific interstitial pneumonia. Semin Respir Crit Care Med. 2012;33(5):440-449.
Google Scholar | Crossref | Medline28. Nunes, H, Schubel, K, Piver, D, et al. Nonspecific interstitial pneumonia: Survival is influenced by the underlying cause. Eur Respir J. 2015;45(3):746-755.
Google Scholar | Crossref | Medline29. Hall, AG, Tilby, MJ. Mechanisms of action of, and modes of resistance to, alkylating agents used in the treatment of haematological malignancies. Blood Rev. 1992 Sep;6(3):163-173.
Google Scholar | Crossref | Medline30. Barnes, H, Holland, AE, Westall, GP, Goh, NS, Glaspole, IN. Cyclophosphamide for connective tissue disease–associated interstitial lung disease. Cochrane Database Syst Rev. 2018;2018(1):CD010908.
Google Scholar31. Lee, J, Kim, YH, Kang, JY, Jegal, Y, Park, SY. Korean guidelines for diagnosis and management of interstitial lung diseases: Part 3. Idiopathic nonspecific interstitial pneumonia. Tuberc Respir Dis. 2019;82(4):277-284.
Google Scholar | Crossref | Medline32. Cyclophosphamide versus Placebo in Scleroderma Lung Disease | NEJM [Internet]. [cited August 5, 2021]. https://www.nejm.org/doi/full/10.1056/nejmoa055120.
Google Scholar33. Tashkin, DP, Roth, MD, Clements, PJ, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): A randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 2016;4(9):708-719.
Google Scholar | Crossref | Medline34. Oldham, JM, Lee, C, Valenzi, E, et al. Azathioprine response in patients with fibrotic connective tissue disease-associated interstitial lung disease. Respir Med. 2016;121:117-122.
Google Scholar | Crossref | Medline35. Zaman, T, Watson, J, Zaman, M. Cryptogenic organizing pneumonia with lung nodules secondary to pulmonary manifestation of Crohn disease. Clin Med Insights Case Rep. 2017;10:1179547617710672.
Google Scholar | SAGE Journals | ISI36. Drakopanagiotakis, F . Cryptogenic and secondary organizing pneumonia. Chest. 2020;139:893-900.
Google Scholar | Crossref37. Swigris, JJ, Berry, GJ, Raffin, TA, Kuschner, WG. Lymphoid interstitial pneumonia: A narrative review. Chest. 2002;122(6):2150-2164.
Google Scholar | Crossref | Medline38. Bonifazi, M, Montero, MA, Renzoni, EA. Idiopathic pleuroparenchymal fibroelastosis. Curr Pulmonol Rep. 2017;6(1):9-15.
Google Scholar | Crossref | Medline39. Lymphocytic Interstitial Pneumonia - Pulmonary Disorders [Internet]. Merck Manuals Professional Edition. [cited August 9, 2021]. https://www.merckmanuals.com/professional/pulmonary-disorders/interstitial-lung-diseases/lymphocytic-interstitial-pneumonia.
Google Scholar40. Strimlan, CV, Rosenow, EC, Weiland, LH, Brown, LR. Lymphocytic interstitial pneumonitis. Review of 13 cases. Ann Intern Med. 1978;88(5):616-621.
Google Scholar | Crossref | Medline41. Koss, MN, Hochholzer, L, Langloss, JM, Wehunt, WD, Lazarus, AA. Lymphoid interstitial pneumonia: Clinicopathological and immunopathological findings in 18 cases. Pathology. 1987;19(2):178-185.
Google Scholar | Crossref | Medline42. Garcia, D, Young, L. Lymphocytic interstitial pneumonia as a manifestation of SLE and secondary Sjogren’s syndrome. BMJ Case Rep. 2013:2013:bcr2013009598.
Google Scholar | Crossref | Medline43. Saito, M, Hatakeyama, S, Wakabayashi, Y, Yanagimoto, S, Takemura, T, Yotsuyanagi, H. A pathologically proven case of adult-onset HIV-related lymphocytic interstitial pneumonia with acute exacerbation treated with steroid and antiretroviral therapy. J Infect Chemother. 2015;21(12):868-872.
Google Scholar | Crossref | Medline44. Chitnis, A, Vyas, PK, Chaudhary, P, Ghatavat, G. Case-based discussion: Lymphocytic interstitial pneumonia a rare presentation in an immunocompetent adult male. Lung India. 2015;32(5):500-504.
Google Scholar | Crossref | Medline45. Piciucchi, S, Tomassetti, S, Casoni, G, et al. High resolution CT and histological findings in idiopathic pleuroparenchymal fibroelastosis: Features and differential diagnosis. Respir Res. 2011;12(1):111.
Google Scholar | Crossref | Medline46. Chua, F, Desai, SR, Nicholson, AG, et al. Pleuroparenchymal fibroelastosis. A review of clinical, radiological, and pathological characteristics. Ann Am Thorac Soc. 2019;16(11):1351-1359.
Google Scholar | Crossref | Medline47. Watanabe, K, Nagata, N, Kitasato, Y, et al. Rapid decrease in forced vital capacity in patients with idiopathic pulmonary upper lobe fibrosis. Respir Investig. 2012;50(3):88-97.
Google Scholar | Crossref | Medline48. Shioya, M, Otsuka, M, Yamada, G, et al. Poorer prognosis of idiopathic pleuroparenchymal fibroelastosis compared with idiopathic pulmonary fibrosis in advanced stage. Can Respir J. 2018;2018:6043053.
Google Scholar | Crossref | Medline49. Boerner, EB, Costabel, U, Wessendorf, TE, Theegarten, D, Bonella, F. Idiopathic pleuroparenchymal fibroelastosis (PPFE) - A case study of a rare entity. Rev Port Pneumol. 2017;23(6):352-355.
Google Scholar | Medline50. Sato, S, Hanibuchi, M, Takahashi, M, et al. A patient with idiopathic pleuroparenchymal fibroelastosis showing a sustained pulmonary function due to treatment with pirfenidone. Intern Med. 2016;55(5):497-501.
Google Scholar | Crossref | Medline51. Hamada, S, Ichiyasu, H, Inaba, M, et al. Prognostic impact of pre-existing interstitial lung disease in non-HIV patients with Pneumocystis pneumonia. ERJ Open Research [Internet]; 2020 [cited August 5, 2021];6(2). https://openres.ersjournals.com/content/6/2/00306-2019.
Google Scholar52. Lavorini, F, Fontana, GA, Usmani, OS. New inhaler devices - the good, the bad and the ugly. Respiration. 2014;88(1):

留言 (0)

沒有登入
gif